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Abstract
Racemic albuterol is an equimolar mixture of two isomers, (R) and (S). Whether (R) and (S)
isomers and the combination of both exert different effects in immune activation is not well
defined. We analyzed the effects of (R+S)-albuterol, (R)-albuterol and (S)-albuterol in a murine
model of allergic pulmonary inflammation and in activated T cells. Mice (C57BL/6) sensitized and
aerosol challenged with the allergen ovalbumin (OVA) or phosphate buffered saline (PBS) were
treated with (R)-albuterol, (S)-albuterol or (R+S)-albuterol. Following administration of (R)-
albuterol, allergen induced bronchoalveolar lavage eosinophils and IgE showed a decrease, albeit
not significantly by ANOVA. As T cells are important in allergic inflammation, we asked whether
(R+S), (R) or (S)-albuterol might differ in effects on T cells and on the activity of the inflammatory
transcription factor NF-κB. In activated T cells, (R)-albuterol administration decreased levels of
inflammatory cytokines and NF-κB activity. These studies suggest that (R)-albuterol decreases
cytokine secretion and NF-κB activity in T cells.
Introduction
Allergic inflammation is characterized by enhanced T cell
activation leading to the production of inflammatory
cytokines and initiation of pathways such as tyrosine
kinase Syk involving mast cells, eosinophils, and immu-
noglobulin E [1-4]. In asthma, this process leads to a phe-
notype characterized by bronchial inflammation and
airway hyperresponsiveness. Activated T cells secrete
cytokines that are pivotal in the pathogenesis of atopic
asthma [5-7]. Further studies have elucidated the key role
played by T cell costimulatory pathways [8,9]
The cornerstone of asthma therapy is inhaled β2-adrener-
gic agonists in combination with inhaled and systemic
steroids. Conventionally, inhaled beta agonists such as
albuterol induce rapid bronchodilation, yet they also
demonstrate anti-inflammatory properties [10,11]. T cells
possess surface β-adrenergic receptors [12] which upon
stimulation activate protein kinase A (PKA) and induce
cAMP, altering cytokine production. Whether beta ago-
nists can impact allergic inflammation by regulating T cell
activation remains undefined.
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Beta agonists are commonly available as racemic mixtures
composed of equimolar mixtures of (R)- and (S)- enanti-
omers. Interestingly, the pharmacokinetic properties and,
at times, the biological effects of these isomers differ. (R)-
albuterol binds to the β2-adrenergic receptor with high
affinity, whereas (S)-albuterol exhibits weak binding to
the β2-adrenergic receptor [13]. Studies of the pharmacok-
inetics of racemic albuterol have shown that elimination
of (R)-albuterol is much more rapid than that of (S)-
albuterol [14,15]. Whereas the (R)-isomer induces bron-
chodilation [16], (S)-albuterol may induce airway hyper-
responsiveness [17]. Also, (R)-albuterol demonstrates
anti-inflammatory effects in both airway smooth muscle
cells and T lymphocytes, while (S)-albuterol does not
[18,19]. Furthermore, β2 agonists may also augment sur-
factant secretion, decrease lung endothelial permeability,
and decrease airway resistance [20].
In this study, we investigated whether albuterol isomers
modulate effects on allergic responses in vivo in a murine
model of allergic inflammation and, in vitro, in activated
T cells. Additionally, we investigated whether activity of
nuclear factor κ-B (NF-κB), which is an important tran-
scription factor involved in the regulation of inflamma-
tory processes including asthma, is regulated by albuterol
isomers [21,22].
Methods
Mice
Six to 8-wk-old C57BL/6 female mice were purchased
from Jackson Laboratory (Bar Harbor, ME, USA). The
mice were maintained according to the guidelines of the
committee on animals of the Harvard Medical School and
the University of California, San Diego animal facility.
Both institutions are accredited by the American Associa-
tion for Accreditation of Laboratory Animal Care. All ani-
mal protocols received prior approval by the institutional
review board.
Ovalbumin Sensitization and Challenge
Mice were sensitized and challenged with the allergen
ovalbumin (OVA) as previously described [9,21,23,24].
OVA mice were sensitized via intraperitoneal injection
with 10 μg of chicken OVA (Sigma, St. Louis, MO, USA)
and 1 mg of A1(OH)2 (alum; Sigma) in 0.2 ml of phos-
phate-buffered saline (PBS; Sigma), followed by a boost-
ing injection on day 7 with the identical reagents. PBS
mice received 1 mg of alum in 0.2 ml of PBS without OVA.
On days 14–20, mice received aerosolized challenge with
6% OVA or PBS, respectively, for 20 min/day via an ultra-
sonic nebulizer (Model 5000; DeVilbiss, Somerset, PA,
USA). All groups were sacrificed at day 21 and analyzed
for the allergic parameters described below.
Bronchoalveolar Lavage Analysis
Each mouse underwent bronchoalveolar lavage [25], as
previously described [9,21]. Cells were resuspended in
RPMI (Sigma) (5 × 105 cells/ml). Slides for differential
cells counts were prepared with cytospin (Shandon, Pitts-
burgh, PA, USA) and fixed and stained with Diff-Quik
(Dade Behring, Newark, DE, USA).
Serum IgE
Blood was obtained by cardiac puncture on day 21. Total
serum IgE levels were determined by ELISA as previously
described [21]. Total serum IgE concentrations were calcu-
lated by using a standard curve generated with commer-
cial IgE standard (BD PharMingen, San Diego, CA, USA).
Cytokine Assays
The cytokines were assayed from supernatant with LIN-
COplex mouse cytokine assays (LINCO Research, St
Charles, Missouri) that are bead-based multiplex sand-
wich immunoassays with a limit detection of less than 5
pg/ml.
Histopathology
For histological analysis, tissue samples from the left lung
were removed from the thoracic cavity and fixed in 4%
paraformaldehyde and routinely processed into paraffin
blocks. Paraffin sections, 5 μm thick, were cut and the tis-
sues were screened with hematoxylin and eosin to verify
the presence of at least three bronchioles per section.
Subcutaneous Insertion of Delivery Pump
On the first day of allergen challenge (day 14) a minios-
motic pump (ALZET Model 1007D, DURECT Corpora-
tion, ALZET Cupertino, CA, USA) containing (R+S)-
albuterol (R)-albuterol, (S)-albuterol or PBS was inserted
subcutaneously. After the mice were anesthetized (Keta-
mine 100 mg/kg & Xylazine 10 mg/kg), the area of pump
implantation was shaved and cleaned with alcohol. An
incision of 1 cm was made between the scapulae, and
pumps were inserted subcutaneously. The pumps con-
tained (R+S)- (100 μg of each isomer in a total volume of
100  μl of PBS), (R)-albuterol, (200 μg/100  μl), (S)-
albuterol (200 μg/100 μl) or PBS (1×/100 μl) and deliv-
ered at a constant rate of 1 mg/kg/day.
Test Compounds
(R)- and (S)- albuterol were provided by Sepracor, Inc
(Marlborough, MA, USA).
Measurement of Systemic Levels of (R)- and (S)- Albuterol
To determine concentrations of (R)-albuterol and (S)-
albuterol in heparinized mouse plasma, 2.0 mL of ammo-
nium acetate buffer (pH 8.7) was added to 0.2 mL of
unknown sample spiked with 20 μL of 0.03 μg/mL n-
methyl albuterol internal standard solution. The samplesRespiratory Research 2008, 9:3 http://respiratory-research.com/content/9/1/3
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were vortexed and put through solid phase extraction
using 3-mL PBA cartridges in a vacuum manifold. Car-
tridges were conditioned with 2 mL of methanolic glacial
acetic acid, 2 mL of methanol, 2 mL of water, and 3 mL of
0.2 M ammonium acetate buffer (pH 8.7). The sample
extracts were transferred to the cartridges which contained
1.0 mL of 0.2 M ammonium acetate buffer (pH 8.7). After
the samples passed through the cartridges, they were
rinsed with 2 mL of 0.1 M ammonium acetate buffer (pH
8.7), 2 mL of water, 1 mL of methanol : water (50 : 50), 2
mL of methanol :water : triethylamine : ammonium
hydroxide (75 : 21 : 2 : 2), 1 mL of methanol : water (50 :
50) and 1 mL of methanol. Samples were eluted with 1.5
mL of methanolic glacial acetic acid. The samples were
placed under vacuum and evaporated to dryness. After
adding 0.150 mL of mobile phase, each tube was vortexed
briefly and transferred to injection vials. The enantiomers
were resolved and quantitated on a high performance liq-
uid chromatographic system equipped with a fluores-
cence detector using an Astec chirobiotic T analytical
column (25 cm × 4.6 mm) and a flow rate of 1.0 mL/
minute. The mobile phase consisted of acetonitrile : meth-
anol : glacial acetic acid : diethylamine (60 : 40 : 0.3 : 0.2).
Analyzed concentrations were calculated using the peak
height ratio of the compound of interest to internal stand-
ard using a linear (1/concentration2-weighted) calibration
model.
Cells
EL4, a T cell cell line (American Type Culture Collection,
Bethesda, MD) was established from a lymphoma
induced in a C57BL/6 mouse by 9,10-dimethyl-1,2-ben-
zanthracene. Murine splenocytes were isolated from
C57BL/6 naïve mice and cultured in RPMI 1640 medium
supplemented with 10% heat-inactivated FCS, 2 mM L-
glutamine, 50 U of penicillin/ml, 50 μg of streptomycin/
ml, and 50 μM 2-ME (complete medium). For activated
samples, cells were cultured with Con A (5 μg/ml) and
PMA (100 ng/ml) for 12 hours and then treated with (R)-
albuterol (10-6  M), (S)-albuterol (10-6  M), or racemic
albuterol [(R)-albuterol (10-6 M)+(S)-albuterol (10-6 M)]
for the next 36 hours. For resting samples, cells were
treated with Con A (5 μg/ml) and PMA (100 ng/ml), (R)-
albuterol (10-6  M), (S)-albuterol (10-6  M), or racemic
albuterol [(R)-albuterol(10-6 M) + (S)-albuterol (10-6 M)]
for 24 hours.
Quantitative Real-time PCR
Total RNA was isolated from EL4 cells and splenocytes
with TRI Reagent (Sigma-Aldrich, St. Louis, MO). Isolated
RNA was reverse transcribed with SuperScript II RNAse
reverse transcriptase (Life Technologies, Carlsbad, CA).
Specific primer pairs for GAPDH (housekeeping gene), IL-
2, IL-6, IL-13, and IFN-γ were designed with the Primer
Express software (Applied Biosystems, Foster City, CA,
USA). The sequences of the forward (FW) and reverse (RE)
primer pairs used in the experiments were as follows:
GAPDH: TTGTGGAAGGGCTCATGACC (FW), TCTTCT-
GGGTGGCAGTGATG (RE) (NM008084), IL-2:
GTCAACAGCGCACCCACTT (FW), TGCTTCCGCTGTA-
GAGCTTG (RE) (NM008366), IL-6: TTCCATCCAGTT-
GCCTTCTTG (FW), GAAGGCCGTGGTTGTCACC (RE)
(NM008355), IL-13: AATCTGTCTGCAGGTGGGCT (FW),
GGCTTCTCACTTTCATTGGCAC (RE) (NM031168), IFN-
γ: AGGTGTCACAACTGCTGCCA (FW), ACACCCGAAT-
GAGCTGCTCT (RE) (NM008337). Direct detection of the
PCR product was monitored by measuring the increase in
fluorescence caused by the binding of SYBR Green to
dsDNA. Using 5 μl of cDNA, 5 μl of primer, and 10 μl of
SYBR Green Master Mix (Applied Biosystems) per well,
the gene-specific PCR products were measured continu-
ously by means of GeneAmp 5700 sequence detection sys-
tem (Applied Biosystems) during 40 cycles. Non-template
controls and dissociation curves were used to detect
primer-dimer conformation and non-specific amplifica-
tion. The threshold cycle (CT) of each target product was
determined and set in relation to the amplification plot of
GAPDH. The CT is the number of PCR cycles required for
the fluorescence signal to exceed the detection threshold
value. The detection threshold was set to the log linear
range of the amplification curve and kept constant (0.3)
for all data analysis. The difference in CT values of two
genes was used to calculate the fold difference.
NF-κB Reporter Assay
The NF-κB promoter luciferase (pGL2) [26] and β-galac-
tosidase reporter gene (pGK) [27] have been described
previously. Each construct (1 μg) was added to EL4 cells
(to 2 × 106) resuspended in nucleofector solution (Amaxa
Biosystems) and electroporated using the C-9 program of
the nucleofector. After 24 hours cells were treated Con A
(5 μg/ml) and PMA (100 ng/ml), [(R)-albuterol(10-6 M) +
(S)-albuterol (10-6  M)], (R)-albuterol (10-6  M) or (S)-
albuterol (10-6 M), for 24 hours. For activated samples,
cells were cultured with Con A (5 μg/ml) and PMA (100
ng/ml) for 12 hours and then treated with [(R)-albuterol
(10-6 M)+(S)-albuterol (10-6 M)], (R)-albuterol (10-6 M)
or (S)-albuterol (10-6 M), for the next 12 hours. Cells were
lysed in reporter lysis buffer (Promega). Then, 10 μl of the
cell lysate was mixed with 100 μl of luciferase assay rea-
gent (Promega), and luciferase activity was measured by a
luminometer (Turner Bio Systems). Luciferase activity was
normalized for transfection efficiency by β-galactosidase
activity measured with Galacto-light systems according to
the manufacturer's instructions (Applied Biosystems,
MA). Fold activation was calculated as the ratio of luci-
ferase versus β-galactosidase activity in experimental sam-
ples compared to media alone.Respiratory Research 2008, 9:3 http://respiratory-research.com/content/9/1/3
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Statistical Analysis
Analysis of variance (ANOVA) was performed by Sigma
Stat software. Bonferroni correction for statistical adjust-
ment of the p value for multiple comparisons was applied
as a post-hoc analysis. Data are reported as means ± SEM.
Statistical significance was defined by p < 0.05.
Results
Allergen-induced pulmonary inflammation is not 
influenced by the insertion of a miniosmotic pump
To analyze the effects of albuterol isomers in vivo in a
murine model of allergic inflammation, we analyzed the
potential immune effects of a delivery device for albuterol
administration i.e. a miniosmotic pump inserted subcuta-
neously. We defined the effects of pump insertion alone
on allergen-induced inflammation in a murine model.
We measured allergen-induced BAL eosinophilia and
total serum IgE in C57BL/6 mice following OVA sensitiza-
tion and challenge and insertion of a subcutaneous mini-
osmotic pump containing PBS (Fig. 1). Consistent with
our previous studies, OVA sensitized and challenged mice
(OVA mice) demonstrated a significant increase in BAL
eosinophilia and total serum IgE as compared with PBS
mice (*p < 0.05, Fig 1A, B). Following the insertion of a
pump containing PBS, OVA mice demonstrated a similar
increase in BAL eosinophilia (†p < 0.01, Fig 1A) and total
serum IgE (†p < 0.01, Fig 1B) compared to PBS mice. OVA
mice compared to OVA mice that had a pump inserted
(OVA+PBS) did not exhibit significant difference in BAL
eosinophilia and total serum IgE.
Administration of albuterol isomers in a pulmonary allergic 
model
We next examined the effects of the albuterol isomers may
influence immune responses. We measured BAL eosi-
nophilia (Fig 2A), total serum IgE (Fig 2B) and pulmonary
histology (Fig 3) in OVA mice following subcutaneous
insertion of a pump containing either (R+S)-, (R)-, (S)-
albuterol or PBS. As expected, OVA+PBS mice had signifi-
cant increase in allergic responses compared with
PBS+PBS mice (Fig 1A). OVA mice treated with (R)-
albuterol demonstrated a decrease in eosinophilia (Fig.
2A) and IgE (Fig. 2B), albeit not significant by ANOVA
analysis. A decrease in the pulmonary infiltrates (Fig. 3) is
also observed. Serum levels of (R) and (S) albuterol were
detected at day 1 and day 7 after pump insertion (not
shown).
Albuterol isomers exert a differential effect on cytokine 
levels following activation of splenocytes
We next determined whether albuterol effects on inflam-
mation observed in vivo may be manifested in analysis of
immune cells. Splenocytes were isolated from naïve
C57BL/6 mice and activated with mitogens ConA and
PMA. Activated splenocytes were incubated with (R+S),
(R), (S) (10-6 M) for 24 hours. IL-2 and IL-13 cytokines
were analyzed by real time PCR (Fig 4A, B). (R)-albuterol
significantly decreased IL-2 and IL-13 mRNA levels. There
was no difference in levels of IL-6 following administra-
tion of albuterol isomers in activated cells (not shown).
Albuterol isomers exert a differential effect on cytokine 
levels following activation of T Cells
T cells are critical for allergic inflammation [6-8,24,28].
We then investigated the effect of albuterol isomers on T
cells using a T cell line (EL-4). We measured cytokine lev-
els in both resting and activated T cells following the
administration of (R+S)-,(R)- or (S)-albuterol (Figure
Pump insertion does not alter allergic immune responses Figure 1
Pump insertion does not alter allergic immune responses. 
Mice were sensitized and challenged with ovalbumin (OVA) 
as described in Methods. On the first day of OVA challenge 
(day 14, see Methods) a miniosmotic pump containing PBS 
(1×/100 ul) was inserted subcutaneously and delivered a con-
stant dose of 25 ul/day. Cell counts were determined by dif-
ferential staining of cells isolated from bronchoalveolar lavage 
(BAL) fluid. Total serum IgE and BAL cytokines (R&D Sys-
tems) were measured by ELISA. (A) BAL eosinoplhlia; (B) 
total serum IgE; (C) BAL IL-13. Data is shown as mean ± SEM 
(n = 8–10 per group). *PBS vs OVA p < 0.01, † PBS+PBS vs 
OVA+PBS p < 0.01.
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5A,B,C). Levels of IL-2, IL-13, IL-6 and IFN-γ were deter-
mined by real time PCR. When T cells were stimulated
with mitogens ConA and PMA (CP) following by incuba-
tion with (R)-albuterol, there was a decrease in mRNA lev-
els of IL-2, IL-13 and IL-6 (Fig. 5A, B, C). IL-2 and IL-13,
but not IL-6 levels, were significantly decreased. There was
no difference in levels of IFN-γ following administration
of albuterol isomers in activated cells (not shown). In rest-
ing T (EL-4) cells there were no significant changes in IL-
2, IL-6, IL-13 or IFN-γ levels following administration of
albuterol isomers (data not shown). Thus, activated T cells
demonstrate differential cytokine production when
treated with albuterol isomers. We also examined
cytokine secretion at the level of protein by bead-based
multiplex sandwich immunoassays and found that (R)-
albuterol significantly decreases IL-2 and IL-13 produc-
tion (Figures 6A, 6B) (*p < 0.05).
(R)-Albuterol decreases NF-κB activity in activated T cells
We previously demonstrated a role for the transcription
factor NF-κB in allergen-induced pulmonary inflamma-
tion and the modulation of T cell subtypes [21,29]. In this
study, we asked whether albuterol isomers would influ-
ence NF-κB activity in T cells. We measured NF-κB activity
in resting and activated EL4 T cells by analysis of a NF-κB
reporter luciferase gene construct following administra-
tion of albuterol isomers (Fig 7). Cells were activated with
the T cell mitogens ConA +PMA (CP). T cells pre activated
with CP, then treated with (R+S)- and (R)-albuterol dis-
play diminution of NF-κB activity when compared with
cells treated with CP alone. In resting T cells, there were no
changes in NF-κB activity after treatment with albuterol
isomers (not shown).
Discussion
Short acting beta agonists, including albuterol, are a
mainstay of asthma therapy due to their ability to pro-
mote bronchodilation; in addition they may display anti-
inflammatory properties [10,11,30,31]. Racemic
albuterol contains equal concentrations of (R)- and (S)-
enantiomers; yet, studies indicate that the (R)-and (S)-iso-
mers may differ in their effects [19,32-34]. In activated T
cells, we show that (R)-albuterol exhibits anti-inflamma-
tory effects that may be mediated by alterations in NF-κB
activity.
The anti-inflammatory properties of beta agonists include
a reduction in proliferation of airway smooth muscle cells
[18,35] as well as inhibition of cytokine-induced release
of eotaxin, a potent eosinophil chemoattractant [36]. Beta
agonists also inhibit the secretion of granular proteins
[37] and the production of superoxide from eosinophils
[32]. Prior studies suggest an anti-inflammatory effect of
beta agonists on T lymphocytes. Beta agonists inhibit T
cell receptor stimulated cytokine production in both
human peripheral blood monocytes [38] and murine T
cell clones [30] effects that may be mediated by β2-adren-
ergic receptor activation of protein kinase A (PKA) [10]
and subsequent inhibition of TNF-α production and NF-
κB activation [39].
(R)- and (S)- albuterol appear to differ in their pharmaco-
logical effects. While (R)- albuterol induces bronchodila-
tion, the (S)- enantiomer shows biological effects
including allergen-induced airway hyperresponsiveness in
a guinea pig model and enhanced contractility in human
bronchi [16]. Increases in intracellular calcium ions
appear to underlie one mechanism by which the (S)-iso-
mer may induce bronchoconstriction [20,40]. (S)-
albuterol also increases the expression of the pro-inflam-
matory mediators, PI3 and NF-κB, in human bronchial
smooth muscle cells [20], while (R)-albuterol decreases
Analysis of allergic parameters following albuterol adminis- tration Figure 2
Analysis of allergic parameters following albuterol adminis-
tration. (A) Mice were sensitized and challenged with OVA. 
On the first day of OVA challenge (day 14, see Methods) a 
miniosmotic pump containing (R+S), (R), (S)-albuterol or PBS 
was inserted subcutaneously (1 mg/kg/day). Cell counts were 
determined by differential staining of cells isolated from BAL 
fluid. Data is shown as mean ± SEM (n = 8–10 per group). (B) 
Total serum IgE levels were measured by ELISA. Data is 
shown as mean ± SEM (n = 8–10 per group).
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proliferation of these cells via activation of PKA and inhi-
bition of PI-3 and NF-κB [18].
Our study examined in vivo administration of (R) + (S)
albuterol isomers. To exclude the possibility that intro-
duction of a subcutaneous delivery device (miniosmotic
pump) alters immune responses, we demonstrated that
insertion of a pump does not alter parameters of allergic
inflammation. Previous data in a murine allergic model
indicate that both (R)- and (S)-albuterol may decrease
allergen-induced pulmonary inflammation and goblet
cell hyperplasia [34]. Our studies and Henderson et al.
exhibit different protocols, timing and methods of aller-
gen administration. Another variable is the time of drug
exposure. In Henderson's studies, the time of drug expo-
sure appears to be 3 times longer than in our protocol
[34]. Also, our murine strain is C57BL/6 while Hender-
son's was Balb/c. As they also did not examine (R+S)
albuteroI, no comparisons can be made with regards to
analysis of the (R+S) group.
(R)-Albuterol decreases pulmonary inflammation after OVA sensitization and aerosol challenge Figure 3
(R)-Albuterol decreases pulmonary inflammation after OVA sensitization and aerosol challenge. On the first day of OVA chal-
lenge (day 14, see Methods) a miniosmotic pump (Alzet) containing (R)- or (S)- albuterol was inserted subcutaneously (200 μg/
100 μl) and delivered a constant dose of 1 mg/kg/day (25 μl/day). A) PBS+pump, B) OVA+ pump, C) PBS+(R), D) OVA+(R), E) 
PBS+(S) and F) OVA+ (S). These pictures are representative of two mice examined in each group. Arrows show inflammatory 
cells. Magnification 10×.
A. B.
E. F.
C. D.Respiratory Research 2008, 9:3 http://respiratory-research.com/content/9/1/3
Page 7 of 9
(page number not for citation purposes)
T cells play an important role in the pathophysiology of
asthma by modulation of inflammatory cytokines and
cells [6,41,42]. Our in vitro studies indicate that albuterol
isomers display differential effects on activated but not
resting T cells. Following activation by T cell mitogens,
ConA and PMA (CP), T cells treated with (R)-albuterol
demonstrated decreased levels of IL-2, IL-6 and IL-13
compared to cells treated with CP alone. These findings
are consistent with previous data indicating differential
effects of albuterol isomers on cell proliferation and
cytokine production in human peripheral blood mono-
cytes [19].
Our findings suggest possible mechanisms for the anti-
inflammatory effects displayed by albuterol isomers that
may occur via T cells. Allergen-induced pulmonary
inflammation is a T cell dependent process mediated by
key inflammatory cytokines which promote effector path-
ways involving eosinophils and IgE [43]. The isomers
(R)-albuterol decreases cytokine protein levels in activated T  cells Figure 6
(R)-albuterol decreases cytokine protein levels in activated T 
cells. (R)-albuterol, (S)-albuterol or racemic albuterol (R + S) 
at a dose (10-6 M) were added to T (EL-4) cells pre-activated 
with mitogens Concanavalin A (Con A, 5 μg/ml) and phorbol 
myristate acetate (PMA, 100 ng/ml) (CP). Supernatant was 
assayed for IL-2 and IL-13 cytokines by bead-based multiplex 
sandwich immunoassay. Data are shown as mean ± SEM (n = 
3) *p < 0.05 (CP vs R).
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(R)-albuterol decreases cytokine levels in activated murine  splenocytes Figure 4
(R)-albuterol decreases cytokine levels in activated murine 
splenocytes. (R)-albuterol (R), (S)-albuterol (S) or racemic 
albuterol (R + S) at a dose (10-6 M) were added to murine 
splenocytes pre-activated with mitogens Concanavalin A 
(Con A, 5 μg/ml) and phorbol myristate acetate (PMA, 100 
ng/ml) (CP), (Fig 3 A, B). RNA was isolated. IL-2 and IL-13 
levels were measured by real time PCR. Fold change is the 
ratio of stimulated to untreated sample. Data are shown as 
mean ± SEM (n = 3). *p < 0.05 (CP vs R).
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(R)-albuterol decreases cytokine mRNA levels in activated T 
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Levels of IL-2, IL-13 and IL-6 (A, B, C) were measured by real 
time PCR. Fold change is the ratio of stimulated to unstimu-
lated sample. Data are shown as mean ± SEM (n = 3) *p < 
0.05 (CP vs R).
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decrease parameters of allergic inflammation in a murine
model [34]. Furthermore, in activated T cells, we show
that (R)-albuterol reduces the inflammatory cytokines, IL-
2 and IL-13. IL-2 is a reliable marker of T cell activation
[44] and IL-13 is well known for its critical role in aller-
gen-induced inflammation [45].
Finally, our data suggest that the effects of (R)-albuterol
may be mediated by alterations in the activity of the
inflammatory transcription factor NF-κB. NF-κB regulates
the expression of a wide range of genes involved in
immune and inflammatory responses [46,47] and plays a
role in the pathogenesis of asthma [21,22,48,49]. Previ-
ous studies indicate that beta agonists exert anti-inflam-
matory effects on monocytic cells via generation of cyclic-
AMP and activation of PKA leading to a decrease in TNF-
α production and NF-κB activation [39]. Also, administra-
tion of albuterol isomers induces differential expression
of NF-κB in airway smooth muscle cells [18,20]. NF-κB
can increase both IL-2 and IL-6 gene expression via bind-
ing to transcriptional promoter elements [25,50]. Our
study indicates that (R)-albuterol decreases cytokine pro-
duction and NF-κB activity in activated T cells.
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